Literature DB >> 3338027

Incidence of cancer of the esophagus in the US by histologic type.

P C Yang1, S Davis.   

Abstract

Data from nine US population-based cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) program from 1973 through 1982 were analyzed to examine demographic characteristics related to the occurrence of the two major types of cancer of the esophagus. The overall annual incidence rate per 100,000 persons was 2.6 for squamous cell carcinoma and 0.4 for adenocarcinoma. The sex ratio for adenocarcinoma varied from one age group to the next and was highest in the 50- to 59-year-old group. It was relatively the same for squamous cell carcinoma. The male-to-female ratio was higher for adenocarcinoma (seven in whites and 10 in blacks) than for squamous cell carcinoma (three and four, respectively). The highest sex-specific ratio for adenocarcinoma occurred in the lower third of the esophagus. Blacks had a fourfold to fivefold higher rate of squamous cell carcinoma than whites, but the rate of adenocarcinoma in blacks was 30% of the rate in whites. The incidence of squamous cell carcinoma in black men and women increased by approximately 30% between 1973 and 1982, and the rate of adenocarcinoma among white men increased 74%. Nearly half of the squamous cell carcinomas occurred in the middle of the esophagus, whereas the majority (79%) of the adenocarcinomas arose in the lower third. These data suggest that the two major histologic types of esophageal cancer may be of different etiologic origin.

Entities:  

Mesh:

Year:  1988        PMID: 3338027     DOI: 10.1002/1097-0142(19880201)61:3<612::aid-cncr2820610332>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  [Leiomyosarcoma of the esophagus. Clinical aspects, diagnosis and therapy based on an individual case].

Authors:  A C Pesarini; H Ernst; C Ell; C Wittekind; E G Hahn
Journal:  Med Klin (Munich)       Date:  1997-04-15

2.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

3.  Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma.

Authors:  Enping Xu; Wenjie Sun; Jian Gu; Wong-Ho Chow; Jaffer A Ajani; Xifeng Wu
Journal:  Carcinogenesis       Date:  2013-06-26       Impact factor: 4.944

4.  Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center.

Authors:  Shayan Irani; Henry P Parkman; Rebecca Thomas; Benjamin Krevsky; Robert S Fisher; Peter Axelrod
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 5.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

6.  Gastroesophageal cancer: understanding the disease process and advancing therapy.

Authors:  John S Macdonald
Journal:  Gastrointest Cancer Res       Date:  2007-03

7.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia.

Authors:  G C Kabat; S K Ng; E L Wynder
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

9.  Time trend and age-period-cohort effects on incidence of esophageal cancer in Connecticut, 1935-89.

Authors:  T Zheng; S T Mayne; T R Holford; P Boyle; W Liu; Y Chen; M Mador; J Flannery
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 10.  Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.

Authors:  Manuel Pera
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.